最新ニュース argenx (NASDAQ:ARGX) 株価情報

argenx

Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.

argenx SE

News

Politics

General

2024 Presidential Election Polls Close In The Following States: GA, IN, KY, SC, VA, VT

Seaport Global analyst Tom Curran initiates coverage on First Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) with a Neutral rating.

Initiation

Analyst Ratings

FSLR

Seaport Global Initiates Coverage On First Solar with Neutral Rating

Scotiabank analyst Greg Harrison maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Sector Perform and raises the price target from $480 to $486.

Price Target

VRTX

Scotiabank Maintains Sector Perform on Vertex Pharmaceuticals, Raises Price Target to $486

Scotiabank analyst Greg Harrison maintains Disc Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRON#NASDAQ">IRON</a>) with a Sector Outperform and raises the price target from $62 to $70.

IRON

Scotiabank Maintains Sector Outperform on Disc Medicine, Raises Price Target to $70

Scotiabank analyst Mario Saric maintains Brookfield Asset Mgmt (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAM#NYSE">BAM</a>) with a Sector Outperform and raises the price target from $55.5 to $59.5.

Scotiabank Maintains Sector Outperform on Brookfield Asset Mgmt, Raises Price Target to $59.5

Scotiabank analyst Andres Coello maintains TIM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TIMB#NYSE">TIMB</a>) with a Sector Outperform and lowers the price target from $24.8 to $23.2.

TIMB

Scotiabank Maintains Sector Outperform on TIM, Lowers Price Target to $23.2

Scotiabank analyst Maher Yaghi maintains BCE (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BCE#TSX">BCE</a>) with a Sector Perform and lowers the price target from C$50.5 to C$47.5.

TSX:BCE

Scotiabank Maintains Sector Perform on BCE, Lowers Price Target to C$47.5

Citigroup analyst Christopher Danely maintains GLOBALFOUNDRIES (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GFS#NASDAQ">GFS</a>) with a Neutral and lowers the price target from $45 to $40.

Citigroup Maintains Neutral on GLOBALFOUNDRIES, Lowers Price Target to $40

NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) passed Apple, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) to become the world's largest publicly traded <a href="https://www.benzinga.com/news/24/11/41751557/nvidia-takes-short-lived-lead-over-apple-in-valuation">company on Tuesday. </a>
The Details: Nvidia ended Tuesday's trading session with a market capitalization of $3.43 trillion, slightly <a href="https://www.benzinga.com/news/24/11/41751557/nvidia-takes-short-lived-lead-over-apple-in-valuation">edging out </a>Apple&#8217;s $3.38 trillion valuation, according to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>. The semiconductor giant's dominance in the artificial intelligence chip market has fueled its exponential growth of more than 200% over the past year.&nbsp;
Read More: <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/11/41724410/nvidia-joining-dow-jones-industrial-average-where-tech-giant-ranks-in-the-index-why-sh">Nvidia Joining Dow Jones Industrial Average: Where Tech Giant Ranks In The Index, Why Sherwin-Williams Addition Could Be More Important</a>
Nvidia briefly passed Apple <a href="https://www.benzinga.com/news/24/06/39386946/microsoft-apple-step-aside-nvidia-is-now-the-most-valuable-public-company-in-the-world">in market cap </a>in June before sliding over the summer.<a href="https://www.cnbc.com/quotes/MSFT/"> </a>Nvidia&#8217;s ascent to the top highlights the growing importance of AI technology and the pivotal role that Nvidia's specialized hardware plays in its development.&nbsp;
Despite Nvidia's remarkable growth over the past year, analysts remain bullish on the company's growth ahead. The three most recent analyst ratings were released by BofA Securities, Goldman Sachs and Morgan Stanley in October with an average price target of $163.33 between the three. There&#8217;s an implied 17.04% upside for Nvidia stock from these analyst ratings.
Last Friday, S&amp;P Dow Jones announced that Nvidia <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/11/41724410/nvidia-joining-dow-jones-industrial-average-where-tech-giant-ranks-in-the-index-why-sh">is joining the Dow Jones Industrial Average on Nov. 8 </a>replacing Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) and joining Apple in the blue-chip index. 
NVDA Price Action: According to data from Benzinga Pro, Nvidia shares ended Tuesday's session 2.84% higher at $139.91.&nbsp;
Read Also:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41690154/shock-october-jobs-report-leaves-fed-in-tight-spot-experts-say-interest-rate-cuts-a">Shock October Jobs Report Leaves Fed In &#8216;Tight Spot:&#8217; Experts Say Interest Rate Cuts Ahead</a></li>
</ul>
Image: Shutterstock

Large Cap

Movers

Tech

AAPL

INTC

NVDA

Nvidia Blows Past Apple To Become World's Most Valuable Company

Lake Street analyst Mark Argento maintains Gaia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GAIA#NASDAQ">GAIA</a>) with a Buy and raises the price target from $6 to $7.

GAIA

Lake Street Maintains Buy on Gaia, Raises Price Target to $7

Lake Street analyst Thomas Flaten maintains Castle Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSTL#NASDAQ">CSTL</a>) with a Buy and raises the price target from $34 to $40.

CSTL

Lake Street Maintains Buy on Castle Biosciences, Raises Price Target to $40

Lake Street analyst Jaeson Schmidt maintains NAPCO Security Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSSC#NASDAQ">NSSC</a>) with a Buy and lowers the price target from $60 to $41.

NSSC

Lake Street Maintains Buy on NAPCO Security Techs, Lowers Price Target to $41

Gulf Island Fabrication (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIFI#NASDAQ">GIFI</a>) .

Guidance

GIFI

Gulf Island Fabrication expect FY2024 adjusted consolidated EBITDA of $11M-$13M.

Lake Street analyst Eric Martinuzzi maintains QuinStreet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNST#NASDAQ">QNST</a>) with a Hold and raises the price target from $20 to $25.

QNST

Lake Street Maintains Hold on QuinStreet, Raises Price Target to $25

Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) .

SNDX

Syndax Pharmaceuticals FY2024 R&D expenses forecast: $245M-$250M.

Loop Capital analyst Rob Sanderson maintains Snap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) with a Buy and raises the price target from $14 to $16.

SNAP

Loop Capital Maintains Buy on Snap, Raises Price Target to $16

Gulfport Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPOR#NYSE">GPOR</a>) .

GPOR

Gulfport Energy Full Year 2024: Drilling and completion capex guidance cut to $325M-$335M.

Loop Capital analyst Garik Shmois maintains Knife River Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNF#NYSE">KNF</a>) with a Buy and lowers the price target from $105 to $100.

Loop Capital Maintains Buy on Knife River Holding, Lowers Price Target to $100

Barclays analyst Blayne Curtis maintains NXP Semiconductors (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) with a Overweight and lowers the price target from $330 to $280.

NXPI

Barclays Maintains Overweight on NXP Semiconductors, Lowers Price Target to $280

It's Election day! Voters are visiting polling locations and social media mavens are sharing opinions and local reports in megathreads, polls and comments on Reddit Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>).
Here are some notable threads to follow for election <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41631795/reddit-remains-a-favorite-for-wall-street-after-emphatic-beat-and-raise-in-q3">coverage on Reddit.&nbsp;</a>
Polls Open: Subreddit r/politics has over 8.5 million subscribers and features a <a href="https://www.reddit.com/r/politics/comments/1gkefi6/rpolitics_2024_us_elections_live_thread_part_59/">live thread</a> with 59 parts titled, "2024 US Elections Live Thread, Part 59" which contains more than 3,200 comments, voter turnout reports from different locations and live commentary on election developments.&nbsp;
Subreddit r/moderatepolitics has 295,000 members and a <a href="https://www.reddit.com/r/moderatepolitics/">poll titled</a> "Who are you voting for in the 2024 US Presidential Election." At the time of publication, 2,100 Redditors selected Harris, 1,300 selected Trump, 301 selected Other and 842 responded with Not Voting.&nbsp;
Read Next: <a href="https://www.benzinga.com/news/earnings/24/10/41612293/reddit-stock-soars-after-strong-q3-results-q4-guidance-above-estimates-dauqs-grow-17-and-more">Reddit Stock Soars After Strong Q3 Results, Q4 Guidance Above Estimates: DAUq&#8217;s Grow 17% And More</a>
Reddit also features local subreddits like r/Pennsylvania, which has <a href="https://www.reddit.com/r/Pennsylvania/comments/1gjutyd/the_election_day_mega_thread/">a thread</a> titled, "The Election Day Mega Thread" where users can find coverage of the crucial swing state and voting guides and polling locations. The thread also provides local polling updates and news with first-hand accounts from voters across the state.&nbsp;
Where To Find Results: FiveThirtyEight, the data journalism outlet, will feature county-by-county data breakdowns as the polling results come in at its r/fivethirtyeight <a href="https://www.reddit.com/r/fivethirtyeight/">subreddit</a>. It also features discussions about polling accuracy and several live election megathreads.&nbsp;&nbsp;
The r/Journalism <a href="https://www.reddit.com/r/Journalism/">subreddit</a> will provide authoritative sources for results, including updates from the Associated Press and major networks, as well as discussions about result reporting methodology.&nbsp;
Reddit&#8217;s election coverage offers a blend of real-time updates and community engagement across various specialized subreddits, though most users recommend keeping multiple sources open for the most complete picture.&nbsp;
RDDT Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Reddit shares ended Tuesday&#8217;s session 12.42% higher at $122.57.
Read Also:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/11/41685913/jpmorgan-to-pay-investors-151-million-after-sec-flags-various-law-violations">JPMorgan To Pay Investors $151 Million After SEC Flags &#8216;Various Law Violations&#8217;</a></li>
</ul>
Photo: Shutterstock

Social Media

RDDT

Redditors Track Election Night: Must-Watch Threads For Trump Vs. Harris Showdown, Other Races

Guggenheim analyst Yatin Suneja raised the firm's price target on Argenx (ARGX) to $665 from $585 and keeps a Buy rating on the shares after the fi...

Argenx price target raised to $665 from $585 at Guggenheim

Truist raised the firm's price target on Argenx (ARGX) to $660 from $540 and keeps a Buy rating on the shares after its Q3 earnings beat. The compa...

Argenx price target raised to $660 from $540 at Truist

Kepler Capital analyst Christophe dombu maintained a Buy rating on arGEN X (0QW0 – Research Report) on October 31 and set a price target of €545.00...

arGEN X (0QW0) Gets a Buy from Kepler Capital

In a report released on October 31, Yaron Werber from TD Cowen maintained a Buy rating on Argenx Se (ARGX – Research Report), with a price target o...

Argenx Se: Strong Market Penetration and Pipeline Expansion Support Buy Rating

Barclays analyst Charles Pitman CFA maintained a Buy rating on arGEN X (0QW0 – Research Report) on November 1 and set a price target of €650.00. Th...

arGEN X (0QW0) Receives a Buy from Barclays

Deutsche Bank raised the firm's price target on Argenx (ARGX) to EUR 525 from EUR 500 and keeps a Hold rating on the shares. Published first on The...

Argenx price target raised to EUR 525 from EUR 500 at Deutsche Bank

JPMorgan analyst James Gordon raised the firm's price target on Argenx (ARGX) to EUR 620 from EUR 570 and keeps an Overweight rating on the shares....

Argenx price target raised to EUR 620 from EUR 570 at JPMorgan

In a report released yesterday, Alex Thompson CFA from Stifel Nicolaus maintained a Buy rating on Argenx Se (ARGX – Research Report), with a price ...

Stifel Nicolaus Sticks to Their Buy Rating for Argenx Se (ARGX)

Scotiabank analyst George Farmer upgraded Argenx (ARGX) to Outperform from Sector Perform with a $715 price target Published first on TheFly – the ...

Argenx upgraded to Outperform from Sector Perform at Scotiabank

Scotiabank upgraded Argenx (ARGX) to Outperform from Sector Perform with a price target of $715, up from $439. The firm sees upside potential for t...

Scotiabank upgrades Argenx on Vyvgart upside, pipeline optionality

ARGX

Press Releases

Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China

argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection)  for Generalized Myasthenia Gravis in China

argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 2024

argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update

argenx to Present at Upcoming Investor Conferences

argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy

argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions

Comments

argenx

ニュース

最新ニュース argenx (NASDAQ:ARGX) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル